Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 13, 2021 07:30 ET | Source: Gennao Bio

Gennao Bio Appoints Chris Duke as Chief Operating Officer and Julie Hambleton, M.D., to Board of Directors

HOPEWELL, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the...
May 10, 2021 08:30 ET | Source: Gennao Bio

Gennao Bio Closes $40 Million Series A Financing to Develop Pipeline of Targeted Nucleic Acid Therapeutics

~ Financing Co-led by OrbiMed and Logos Capital to Support Advancement of Proprietary Gene Monoclonal Antibody Platform (GMAB) ~ ~ Stephen Squinto, Ph.D., Appointed Chief Executive Officer and...
April 10, 2021 08:30 ET | Source: Gennao Bio

Gennao Bio Presents New Data on Novel Gene Monoclonal Antibody Platform Technology at the American Association for Cancer Research (AACR) 2021 Annual Meeting

~ Preclinical data show the utility of Gennao’s proprietary first-in-class monoclonal antibody 3E10-D31N (GMABD31N), a cell penetrating antibody, to non-covalently bind to and systemically deliver...
March 10, 2021 16:31 ET | Source: Gennao Bio

Gennao Bio Announces Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) 2021 Annual Meeting

~ Presentation to highlight the potential of Gennao’s proprietary, non-viral gene monoclonal antibody (GMAB) platform technology to systemically deliver immunostimulatory RNAs to tumors and suppress...